Collaborating to strengthen digital health expertise.
AstraZeneca announced today that it has established a new collaboration with IBM Sweden through the BioVentureHub. From now on, small and medium-sized enterprises (SMEs) connected to IBM Sweden or AstraZeneca’s BioVentureHub will be offered access to the other partner’s open innovation platform. The collaboration aims to stimulate growth of SMEs, support knowledge exchange between the life science and digital technology industries, and strengthen digital health expertise.
“We are seeing more and more life science companies going digital and digital companies going life science; and there is often a lack of complementary skills and know-how. Our exciting collaboration with IBM will provide SMEs and research groups with a unique, non-competitive, collaboration environment that can contribute with both pockets of expertise and foster breakthrough digital health solutions. Besides supporting growth strategies for Swedish SMEs, we also hope the collaboration will help attract international digital health companies to Sweden,” says Magnus Björsne, CEO, AstraZeneca BioVentureHub.
Click here to see the full press release (in Swedish) - PDF versions in SWE and ENG below.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.